Free Trial

Arrowhead Pharmaceuticals (ARWR) SEC Filings & 10K Form

Arrowhead Pharmaceuticals logo
$12.87 +0.53 (+4.29%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$12.87 0.00 (0.00%)
As of 04/15/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Arrowhead Pharmaceuticals SEC Filings

DateFilerForm TypeView
04/11/2025
5:20 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2025
3:35 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/09/2025
3:44 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/17/2025
4:45 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2025
3:46 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/07/2025
3:15 PM
Arrowhead Pharmaceuticals (Filer)
Form 424B7
03/05/2025
5:32 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
4:48 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
8:31 AM
Arrowhead Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
Form SCHEDULE 13G/A
02/10/2025
5:23 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
4:57 PM
Arrowhead Pharmaceuticals (Issuer)
INGRAM DOUGLAS S (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
02/07/2025
4:57 PM
Arrowhead Pharmaceuticals (Issuer)
INGRAM DOUGLAS S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2025
5:41 AM
Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SCHEDULE 13G
01/27/2025
6:22 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
3:43 PM
Arrowhead Pharmaceuticals (Subject)
OLUKOTUN ADEOYE Y (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2025
8:27 PM
Arrowhead Pharmaceuticals (Issuer)
Myszkowski Kenneth Allen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
8:28 PM
Arrowhead Pharmaceuticals (Issuer)
O'Brien Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
8:28 PM
Arrowhead Pharmaceuticals (Issuer)
Hamilton James C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
3:49 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2025
4:01 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2025
3:31 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
5:07 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
4:48 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
4:33 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
4:40 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
4:26 PM
Arrowhead Pharmaceuticals (Subject)
Myszkowski Kenneth Allen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
4:19 PM
Arrowhead Pharmaceuticals (Subject)
Hamilton James C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2025
4:05 PM
Arrowhead Pharmaceuticals (Subject)
O'Brien Patrick (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2025
3:16 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/30/2024
4:12 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/27/2024
3:23 PM
Arrowhead Pharmaceuticals (Subject)
OLUKOTUN ADEOYE Y (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2024
3:39 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
3:16 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/20/2024
5:04 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
PERRY MICHAEL S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
Ferrari Mauro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
OLUKOTUN ADEOYE Y (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/20/2024
5:05 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
5:15 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Elon Reveals Why There Soon Won’t Be Any Money For Social Security (Ad)

Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.

See why thousands of forward-thinking retirement savers are now requesting this FREE 2025 Wealth Pro
12/18/2024
5:18 PM
Arrowhead Pharmaceuticals (Issuer)
GIVEN DOUGLAS B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
5:19 PM
Arrowhead Pharmaceuticals (Issuer)
Waddill William D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2024
3:41 PM
Anzalone Christopher Richard (Reporting)
Arrowhead Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2024
4:06 PM
Arrowhead Pharmaceuticals (Subject)
GIVEN DOUGLAS B (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2024
3:53 PM
Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2024
3:44 PM
Arrowhead Pharmaceuticals (Subject)
Waddill William D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2024
3:15 PM
Arrowhead Pharmaceuticals (Subject)
GIVEN DOUGLAS B (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/15/2024
7:34 PM
Arrowhead Pharmaceuticals (Issuer)
Lu Hongbo (Reporting)
Form 5
Annual statement of changes in beneficial ownership of securities  
11/14/2024
8:38 AM
Arrowhead Pharmaceuticals (Subject)
Avoro Capital Advisors LLC (Filed by)
Form SC 13G
10/16/2024
8:15 AM
Arrowhead Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
07/03/2024
4:27 PM
Arrowhead Pharmaceuticals (Issuer)
Oliver Tracie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
3:09 PM
Arrowhead Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2024
5:04 PM
Arrowhead Pharmaceuticals (Issuer)
Vakiener Victoria (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/02/2024
1:39 PM
Arrowhead Pharmaceuticals (Subject)
Vakiener Victoria (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:ARWR) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners